Aspira Women's Health to Present at the A.G.P. Healthcare Showcase on May 21
Aspira Women's Health to Present at the A.G.P. Healthcare Showcase on May 21
AUSTIN, Texas, May 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the Alliance Global Partner's Healthcare Showcase taking place virtually on Tuesday, May 21, 2024.
得克薩斯州奧斯汀，2024年5月16日（GLOBE NEWSWIRE）——專注於開發婦科疾病診斷工具的生物分析女性健康公司Aspira Women's Health Inc.（“Aspira” 或 “公司”）（納斯達克股票代碼：AWH）今天宣佈，管理層將在2024年5月21日星期二虛擬舉行的聯盟全球合作伙伴醫療保健展示會上介紹公司概況。
|
Presentation Details: | |
| Date: | Tuesday, May 21, 2024 |
| Time: | 11:00 am EST |
| Webcast: | Click HERE to register for the conference and view the presentation |
| 演示詳情： | |
| 日期： | 2024 年 5 月 21 日，星期二 |
| 時間： | 美國東部標準時間上午 11:00 |
| 網絡直播： | 點擊這裏 註冊會議並查看演示文稿 |
Management will be available for one-on-one meetings with investors who are registered for the conference.
管理層將可以與註冊參加會議的投資者進行一對一的會面。
About Aspira Women's Health Inc.
Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.
關於 Aspira 女性健康公司
Aspira Women's Health Inc. 致力於發現、開發和商業化基於人工智能的無創檢測，以幫助診斷婦科疾病。
OvaWatch and Ova1Plus are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is comprised of two FDA-cleared tests, Ova1 and Overa, to assess the risk of ovarian malignancy in women planned for surgery.
OvaWatch 還有 Ova1Plus 作爲 ovaSuite 提供給臨床醫生軍士長。他們共同提供唯一全面的血液檢查產品組合，以幫助每年被診斷患有附件腫塊的120多萬美國女性發現卵巢癌。OVAWatch提供的陰性預測值爲99％，用於評估女性的卵巢癌風險，初步臨床評估表明腫塊不確定或良性，因此手術可能爲時過早或不必要。Ova1Plus 包含兩項經美國食品藥品管理局批准的測試，即 Ova1 和 Overa，以評估計劃接受手術的女性患卵巢惡性腫瘤的風險。
Our in-development test pipeline is designed to expand our ovarian cancer portfolio and addresses the tremendous need for noninvasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, our OvaMDxSM risk assessment is designed to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, EndoCheckSM is the first-ever noninvasive test designed to identify endometriomas, one of the most commonly occurring forms of endometriosis. The EndoMDxSM test is designed to combine microRNA and protein biomarkers with patient data to identify all endometriosis.
我們正在開發的測試管道旨在擴大我們的卵巢癌產品組合，滿足對子宮內膜異位症無創診斷的巨大需求，子宮內膜異位症是一種影響全球數百萬女性的使人衰弱的疾病。在卵巢癌中，我們的 OvamdX軍士長 風險評估旨在將microRNA和蛋白質生物標誌物與患者數據相結合，以進一步提高我們當前測試的靈敏度和特異性。在子宮內膜異位症中，EndoCheck軍士長 是有史以來第一項旨在識別子宮內膜瘤的無創檢測，子宮內膜瘤是最常見的子宮內膜異位症形式之一。EndomDX軍士長 該測試旨在將microRNA和蛋白質生物標誌物與患者數據相結合，以識別所有子宮內膜異位症。
Investor Relations Contact:
Torsten Hombeck, Ph.D.
Chief Financial Officer
Aspira Women's Health
Investors@aspirawh.com
投資者關係聯繫人：
託斯滕·霍姆貝克博士
首席財務官
Aspira 女性健康
Investors@aspirawh.com